Capstone Investment Advisors’s Royalty Pharma RPRX Stock Holding History

Capstone Investment Advisors’s Portfolio RPRX Stock Details RPRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$695K	Buy	+14,481	New	+$634K	﹤0.01%	997
2025 Q4	–	Sell	-169,255	Closed	-$5.97M	–	1981
2025 Q3	$5.97M	Buy	169,255 +150,455	+800%	+$5.45M	0.01%	431
2025 Q2	$677K	Buy	+18,800	New	+$623K	﹤0.01%	1001
2024 Q2	–	Sell	-17,841	Closed	-$542K	–	2407
2024 Q1	$542K	Buy	+17,841	New	+$526K	﹤0.01%	1511
2023 Q4	–	Sell	-7,700	Closed	-$209K	–	2358
2023 Q3	$209K	Buy	+7,700	New	+$229K	﹤0.01%	1794

Other funds holding RPRX

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Capstone Investment Advisors's RPRX Position: Q1 2026 in Review

Capstone Investment Advisors opened a new position in Royalty Pharma (RPRX) in Q1 2026: 14,481 shares worth $695K. The stake represents ﹤0.01% of the portfolio and ranks #997 among its holdings. This is a return to the name: Capstone Investment Advisors previously reported a position in RPRX as recently as Q3 2025.

Capstone Investment Advisors first reported a position in RPRX in Q3 2023 and has held it in 5 quarters since. The position peaked at $5.97M in Q3 2025. 587 funds tracked by Wall St. Rank hold RPRX as of Q1 2026.

Capstone Investment Advisors held 14,481 shares of Royalty Pharma worth $695K as of Q1 2026.
Royalty Pharma was a new Capstone Investment Advisors position in Q1 2026.
Royalty Pharma made up ﹤0.01% of Capstone Investment Advisors's portfolio in Q1 2026, its #997 holding.
Capstone Investment Advisors first reported a position in Royalty Pharma in Q3 2023 and has held it in 5 quarters since.
Capstone Investment Advisors's Royalty Pharma position peaked at $5.97M in Q3 2025.
587 funds tracked by Wall St. Rank held Royalty Pharma as of Q1 2026.

Based on Capstone Investment Advisors's 13F filing for Q1 2026, filed 15 May 2026.